Victory Capital Management
IGMS

Victory Capital Management’s IGM Biosciences IGMS Stock Holding History

Victory Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-90,200
Closed -$1.53M – 2637
2022
Q4 		$1.53M Buy
90,200
+9,750
+12% +$195K ﹤0.01% 1535
2022
Q3 		$1.83M Sell
80,450
-813
-1% -$16.4K ﹤0.01% 1478
2022
Q2 		$1.47M Buy
81,263
+70,899
+684% +$1.26M ﹤0.01% 1576
2022
Q1 		$173K Sell
10,364
-21,247
-67% -$396K ﹤0.01% 2433
2021
Q4 		$927K Sell
31,611
-2,528
-7% -$126K ﹤0.01% 1876
2021
Q3 		$2.25M Sell
34,139
-3,369
-9% -$258K ﹤0.01% 1563
2021
Q2 		$3.12M Sell
37,508
-2,303
-6% -$171K ﹤0.01% 1500
2021
Q1 		$3.05M Buy
39,811
+7,897
+25% +$719K ﹤0.01% 1517
2020
Q4 		$2.82M Buy
31,914
+17,917
+128% +$1.26M ﹤0.01% 1400
2020
Q3 		$1.03M Buy
+13,997
New +$829K ﹤0.01% 1688
2020
Q2 		– Sell
-2,434
Closed -$136K – 2856
2020
Q1 		$136K Sell
2,434
-1,255
-34% -$55K ﹤0.01% 2438
2019
Q4 		$141K Buy
+3,689
New +$92.7K ﹤0.01% 2416

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Victory Capital Management's IGMS Position: Q1 2023 in Review

Victory Capital Management sold out of IGM Biosciences (IGMS) in Q1 2023, closing a stake of 90,200 shares — an estimated $1.53M sold.

Victory Capital Management first reported a position in IGMS in Q4 2019 and held it in 12 quarters. The position peaked at $3.12M in Q2 2021. 74 funds tracked by Wall St. Rank hold IGMS as of Q1 2023.

  • Victory Capital Management reported no remaining IGM Biosciences position as of Q1 2023 after selling out during the quarter.
  • Victory Capital Management sold 90,200 IGM Biosciences shares in Q1 2023, an estimated $1.53M.
  • Victory Capital Management first reported a position in IGM Biosciences in Q4 2019 and held it in 12 quarters.
  • Victory Capital Management's IGM Biosciences position peaked at $3.12M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.